Conditioned media from drug‐treated KRAS mutant CRC cells were applied to both sensitive and MIF knockout cell lines, which were treated with refametinib, and then, cell viability was determined (Figs 3A and S7). The gene discussed is KRAS; the disease is colorectal carcinoma.